All entries for: Biologic

August 6, 2026

Emergent Biosolutions

Layoffs

Gaithersburg, Maryland

501-1,000 employees

“To align resourcing to current needs, Emergent BioSolutions is restructuring its business, a move that includes letting go of 93 employees across the company and eliminating 21 vacant positions. Emergent announced the plans in its second quarter earnings release and provided additional details in a related SEC filing.

The layoffs represent a small number of the company’s overall workforce, which was about 900 employees as of Dec. 31, 2025.

Emergent, which develops and manufactures medicines for diseases including smallpox and makes Narcan, which treats opioid overdoses, did not specify which locations the workforce reduction will affect. However, the announcement noted the closure of wet laboratories in Gaithersburg, Maryland, where the company is based.

The restructuring includes eliminating the role of chief medical officer, head of research and development, pushing Simon Lowry out of Emergent effective Aug. 19. The company is also creating a new “growth organization” that combines research and development, business development and strategy into one function. Stephanie Duatschek will lead that team in her new role as executive vice president, chief growth officer. Previously, she was senior vice president, chief global strategy and franchise development officer.

Emergent expects to incur costs of $10 million to $11.5 million in connection with the restructuring. As of June 30, the company’s capital resources included $139.7 million in cash and cash equivalents.”

Disease Area: Antiviral, Infectious Diseases

Drug Type: Biologic, Small Molecule

Source

August 5, 2026

United Therapeutics Corp

Neutral Outlook

Silver Spring, MD

1,001-5,000 employees

While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.

Disease Area: Cardiology, Oncology, Rare Diseases, Respiratory Diseases

Drug Type: Biologic, Small Molecule

Source

August 5, 2026

Sarepta Therapeutics, Inc.

Neutral Outlook

Cambridge, MA

501-1,000 employees

The U.S. government and individual states continue to aggressively pursue healthcare reform, which includes ongoing attempts to manage utilization as well as control and/or lower the cost of prescription drugs and biologics. Recent years have seen a number of reform initiatives focused on drug pricing and payment. For example, the Inflation Reduction Act (“IRA”), passed in 2022, has had and will likely continue to have a significant impact on the pharmaceutical industry.

Disease Area: Multiple, Neurological Diseases, Rare Diseases

Drug Type: Biologic, Small Molecule

Source

August 5, 2026

BeOne Medicines Ltd.

Neutral Outlook

Cambridge, MA

10,000+ employees

The IRA includes several provisions that may impact our business to varying degrees, including provisions that create a $2,000 out-of-pocket cap for Medicare Part D beneficiaries, impose new manufacturer financial liability on all drugs in Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, require companies to pay rebates to Medicare for drug prices that increase faster than inflation, and delay the rebate rule that would require pass through of pharmacy benefit manager rebates to beneficiaries.

Disease Area: Oncology

Drug Type: Biologic, Small Molecule

Source

August 5, 2026

Biocryst Pharmaceuticals Inc

Neutral Outlook

Durham, NC

501-1,000 employees

The full effect of the IRA on our business and the healthcare industry in general is not yet known.

Disease Area: Rare Diseases

Drug Type: Biologic, Small Molecule

Source

August 5, 2026

Adicet Bio, Inc.

Neutral Outlook

Redwood City, CA

51-200 employees

The effects of the IRA on our business and the healthcare industry in general is not yet known.

Disease Area: Immune Diseases

Drug Type: Biologic

Source

August 5, 2026

Amgen Inc

Neutral Outlook

Thousand Oaks, CA

10,000+ employees

Further, the IRA inflation penalties allow CMS to collect rebates from manufacturers if Medicare price increases outpace inflation, and several of our products have been subject to such IRA inflation rebates. The IRA’s Medicare price setting and Medicare redesign have had, and are likely to have, an adverse effect on our sales, our business and our results of operations, and such impact is expected to increase through the end of the decade and will depend on factors including the extent of our portfolio’s exposure to Medicare reimbursement, the rate of inflation over time, the number of our products selected for Medicare price setting and the timing of market entry of generic or biosimilar competition. Further, following the enactment of the IRA, the environment remains dynamic, and U.S. policymakers continue to demonstrate interest in health care and drug pricing changes as well as potential changes affecting intellectual property.

Disease Area: Cardiology, Metabolic Diseases, Multiple, Oncology

Drug Type: Biologic, Small Molecule

Source

August 5, 2026

Coherus Oncology Inc

Neutral Outlook

Redwood City, CA

201-500 employees

Furthermore, the impact of the IRA on our business and the pharmaceutical industry generally is currently unknown. We expect to experience pricing pressures in connection with the sale of our product and any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes.

Disease Area: Oncology

Drug Type: Biologic

Source

August 5, 2026

Pfizer - New York

Layoffs

New York, NY

10,000+ employees

“Pfizer is adding $2.5 billion in cuts to an ongoing restructuring, with much of the new reduction coming from technology and simplification efforts across the New York pharma’s commercial, R&D and manufacturing functions.

The cuts under Pfizer’s Realigning Our Cost Base Program are expected to save $1 billion, the company announced Aug. 4 in its second-quarter earnings release. Most savings will occur between 2027 and 2029, but not for free: the program carries a one-time cost of $2 billion for digital enablement, implementation and severance.

A company spokesperson declined to give further details on how severance will be paid, whether any jobs will be affected, or what technological changes are planned.”

Disease Area: Antiviral, Cardiology, Dermatology, Gastrointestinal, Immune Diseases, Infectious Diseases, Metabolic Diseases, Multiple, Oncology

Drug Type: Biologic, Small Molecule

Source

August 4, 2026

ImmunityBio, Inc.

Neutral Outlook

San Diego, CA

501-1,000 employees

We cannot predict the full impact of the Executive Orders and other actions focused on reducing prescription drug prices or increasing domestic drug manufacturing capacity, or other measures that may be implemented by the current administration related to drug pricing, drug supply chain and manufacturing in the U.S.

Disease Area: Oncology

Drug Type: Biologic

Source